These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 33650758

  • 21. Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.
    Meng A, Humeniuk R, Jürgensmeier JM, Hsueh CH, Matzkies F, Grant E, Truong H, Billin AN, Yu H, Feng J, Kwan E, Tarnowski T, Nelson CH.
    Clin Pharmacol Ther; 2022 Feb; 111(2):416-424. PubMed ID: 34623640
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
    Muirhead GJ, Osterloh IH, Whaley S, van den Berg F.
    J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
    [Abstract] [Full Text] [Related]

  • 23. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
    Banfield C, Scaramozza M, Zhang W, Kieras E, Page KM, Fensome A, Vincent M, Dowty ME, Goteti K, Winkle PJ, Peeva E.
    J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
    Peeva E, Hodge MR, Kieras E, Vazquez ML, Goteti K, Tarabar SG, Alvey CW, Banfield C.
    Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897
    [Abstract] [Full Text] [Related]

  • 25. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
    Tam CS, Ou YC, Trotman J, Opat S.
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.
    MacGlashan D, Honigberg LA, Smith A, Buggy J, Schroeder JT.
    Int Immunopharmacol; 2011 Apr; 11(4):475-9. PubMed ID: 21238622
    [Abstract] [Full Text] [Related]

  • 27. A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.
    Tsai M, Chrones L, Xie J, Gevorkyan H, Macek TA.
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3787-3795. PubMed ID: 27572830
    [Abstract] [Full Text] [Related]

  • 28. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.
    Sakurai Y, Nishimura A, Kennedy G, Hibberd M, Jenkins R, Okamoto H, Yoneyama T, Jenkins H, Ashida K, Irie S, Täubel J.
    Clin Transl Gastroenterol; 2015 Jun 25; 6(6):e94. PubMed ID: 26111126
    [Abstract] [Full Text] [Related]

  • 29. A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants.
    Sun ALA, Gillies JD, Shen Y, Deng H, Xue F, Ma Y, Song L.
    Clin Transl Sci; 2024 Jul 25; 17(7):e13857. PubMed ID: 38949195
    [Abstract] [Full Text] [Related]

  • 30. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A, Serafini L, Xing W, Czerwieniec G, Steiner B, Wang T, Brendza KM, Lutz JD, Keegan KS, Ray AS, Schultz BE, Sakowicz R, Feng JY.
    Biochim Biophys Acta Gen Subj; 2020 Apr 25; 1864(4):129531. PubMed ID: 31953125
    [Abstract] [Full Text] [Related]

  • 31. Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
    Kawahata W, Asami T, Kiyoi T, Irie T, Kashimoto S, Furuichi H, Sawa M.
    J Med Chem; 2021 Oct 14; 64(19):14129-14141. PubMed ID: 34529443
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.
    Ramanathan S, Di Paolo JA, Jin F, Shao L, Sharma S, Robeson M, Kearney BP.
    Clin Drug Investig; 2017 Feb 14; 37(2):195-205. PubMed ID: 27785737
    [Abstract] [Full Text] [Related]

  • 33. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.
    Clin Ther; 2010 Jun 14; 32(6):1188-204. PubMed ID: 20637971
    [Abstract] [Full Text] [Related]

  • 34. Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A.
    Yin W, Arkilo D, Khudyakov P, Hazel J, Gupta S, Quinton MS, Lin J, Hartman DS, Bednar MM, Rosen L, Wendland JR.
    Br J Clin Pharmacol; 2021 Dec 14; 87(12):4756-4768. PubMed ID: 33990969
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
    Han K, Cremer J, Elston R, Oliver S, Baptiste-Brown S, Chen S, Gardiner D, Davies M, Saunders J, Hamatake R, Losos J, Leivers M, Hood S, van der Berg F, Paff M, Ritter JM, Theodore D.
    Clin Pharmacol Drug Dev; 2019 Aug 14; 8(6):790-801. PubMed ID: 30861337
    [Abstract] [Full Text] [Related]

  • 39. A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events.
    Goldsmith P, Affinito J, McCue M, Tsai M, Roepcke S, Xie J, Gertsik L, Macek TA.
    Drugs R D; 2017 Dec 14; 17(4):631-643. PubMed ID: 29103081
    [Abstract] [Full Text] [Related]

  • 40. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M, Anzures-Cabrera J, Turnbull L, Phelan M.
    Clin Drug Investig; 2011 Dec 14; 31(5):325-35. PubMed ID: 21366361
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.